The tropomyosin 3.1/3.2 inhibitor ATM-3507 alters B-cell actin dynamics and impairs the growth and motility of diffuse large B-cell lymphoma cell lines
Publication Date
Publication Journal
Author(s)
Abhishek Bedi, Kate Choi, Alyssa Iskierski, and Michael R. Gold
Tropomyosin proteins support the cytoskeleton and cell membrane dynamics that underlie processes including cell migration and division, but their role in B-lymphocyte immune cells has not been explored. In this study, the authors treated B cells with a chemical compound that inactivates two key tropomyosin proteins, Tpm3.1 and Tpm3.2. They found that this compound impaired the ability of B cells to remodel their cytoskeleton and undergo cell spreading. Importantly, this compound also inhibited the growth and motility of diffuse large B-cell lymphoma (DLBCL) cells. These results suggest that these tropomyosin proteins, and the processes they orchestrate, may be promising targets for drugs aimed at limiting the growth and spread of B cell cancers.